首頁 › 非小細胞肺癌 › 德克薩斯州 › Fort Worth
Fort Worth, TX 的 非小細胞肺癌 臨床試驗
18 項針對 非小細胞肺癌 的研究正在 Fort Worth（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
招募中1 期
- START Center for Clinical Research, Fort Worth
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
招募中3 期
- The Center For Cancer And Blood Disorders, Fort Worth
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
招募中2 期
- START Fort Worth, Fort Worth
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
招募中3 期
- Texas Oncology - DFW, Fort Worth
- The Center for Cancer and Blood Disorders, Fort Worth
- The Center for Cancer and Blood Disorders, Burleson · 距離 13 英里
- 還有 1 項
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
招募中3 期
- Texas Oncology - DFW, Fort Worth
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
招募中3 期
- The Center for Cancer and Blood Disorders, Fort Worth
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
招募中3 期
- Research Site, Fort Worth
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
招募中3 期
- Research Site, Fort Worth
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
招募中3 期
- Clinical Study Site, Fort Worth
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
招募中1/2 期
- Start Dfw, Fort Worth
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
招募中3 期
- JPS Health Network, Fort Worth
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
招募中1 期
- Texas Oncology - DFW, Fort Worth
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
招募中1/2 期
- USOR Texas Oncology, Fort Worth
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
招募中1 期
- UT Southwestern - Simmons Cancer Center - Fort Worth, Fort Worth
ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer
招募中2 期
- Start Ccbd, Llc, Fort Worth
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
招募中1 期
- START Dallas Fort Worth, LLC, Fort Worth
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
招募中1 期
- START Dallas Fort Worth, LLC, Fort Worth
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
招募中1 期
- START Dallas, Fort Worth
其他城市的 非小細胞肺癌 試驗
- Houston, TX145 項研究
- New York City, NY121 項研究
- Arlington, VA104 項研究
- Nashville, TN97 項研究
- Boston, MA90 項研究
- Los Angeles, CA87 項研究
- St. Louis, MO73 項研究
- Chicago, IL61 項研究
- Baltimore, MD60 項研究
- San Antonio, TX59 項研究
- Columbus, OH57 項研究
- Washington, DC55 項研究
Fort Worth 的其他研究
- 卵巢癌17 項研究
- 子宮內膜癌12 項研究
- 乳癌12 項研究
- 癌症（所有類型）9 項研究
- 前列腺癌9 項研究
- 三陰性乳癌7 項研究
- 黃斑部病變7 項研究
- 潰瘍性結腸炎7 項研究
- 腎臟癌（腎細胞癌）7 項研究
- 心臟衰竭7 項研究
- 轉移性癌症7 項研究
- 大腸直腸癌7 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。